利妥昔单抗联合化疗对弥漫大 B 细胞淋巴瘤患者血清外泌体 miR-451a 表达的影响。

Effect of rituximab combined with chemotherapy on the expression of serum exosome miR-451a in patients with diffuse large b-cell lymphoma.

机构信息

Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

出版信息

Eur Rev Med Pharmacol Sci. 2019 Feb;23(4):1620-1625. doi: 10.26355/eurrev_201902_17121.

DOI:10.26355/eurrev_201902_17121

PMID:30840285

Abstract

OBJECTIVE

The aim of this study was to investigate the influence of rituximab combined with chemotherapy on the expression of serum exosome micro ribonucleic acid 451a (miR-451a) in patients with diffuse large B-cell lymphoma (DLBCL), and to explore the possible underlying mechanism.

PATIENTS AND METHODS

89 DLBCL patients (DLBCL group) receiving rituximab combined with chemotherapy were enrolled in this study. Meanwhile, 48 healthy controls (control group) were enrolled as well. Serum samples were collected from all patients before and after treatment, respectively. At the same time, blood samples of healthy people were collected, and serum exosome was extracted. Real-Time fluorescence-quantitative Polymerase Chain Reaction (qRT-PCR) was applied to measure the expression level of serum exosome miR-451a. Receiver operating characteristics (ROC) curve was used to evaluate the diagnostic efficiency of miR-451a. Statistical Product and Service Solutions (SPSS) 22.0 was employed for statistical analysis. Two-sided 95% confidence interval (CI) was used for all tests, and p<0.05 was considered statistically significant.

RESULTS

The expression level of miR-451a in the DLBCL group was significantly lower than that of the control group. The area under the ROC curve (AUC) for the diagnostic efficacy of serum exosome miR-451a for DCBCL was 0.7147. After treatment, the level of serum exosome miR-451a in patients was significantly increased, whereas was still lower than the normal level. The AUC of ROC for evaluating the effect of serum exosome miR-451a in DCBCL was 0.8038.

CONCLUSIONS

Serum exosome miR-451a has moderate diagnostic efficiency for DLBCL. Moreover, miR-451a can act as an indicator for evaluating the efficacy of rituximab combined with chemotherapy in the DLBCL treatment.

摘要

目的

本研究旨在探讨利妥昔单抗联合化疗对弥漫性大 B 细胞淋巴瘤（DLBCL）患者血清外泌体微小核糖核酸 451a（miR-451a）表达的影响，并探讨其可能的作用机制。

方法

选取 89 例接受利妥昔单抗联合化疗的 DLBCL 患者（DLBCL 组）作为研究对象。同时选取 48 例健康对照者（对照组）。分别采集所有患者治疗前后的血清样本，同时采集健康人的血样，提取血清外泌体。采用实时荧光定量聚合酶链反应（qRT-PCR）检测血清外泌体 miR-451a 的表达水平。采用受试者工作特征（ROC）曲线评价 miR-451a 的诊断效能。采用统计产品与服务解决方案（SPSS）22.0 进行统计学分析。所有检验均采用双侧 95%置信区间（CI），p<0.05 为差异有统计学意义。

结果

DLBCL 组 miR-451a 的表达水平明显低于对照组。血清外泌体 miR-451a 对 DLBCL 的诊断效能的曲线下面积（AUC）为 0.7147。治疗后患者血清外泌体 miR-451a 水平明显升高，但仍低于正常水平。血清外泌体 miR-451a 对 DLBCL 疗效评估的 ROC 曲线 AUC 为 0.8038。